NCT02400463View on ClinicalTrials.gov

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

October 10, 2019

Study Completion Date

January 7, 2020

Conditions
Hemophagocytic Syndrome (HPS)
Interventions
DRUG

Ruxolitinib

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT02400463 - A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | Biotech Hunter | Biotech Hunter